Figure 1.
Treatment-induced changes in body weight and glucose. Changes in A, body weight; B, HbA1c%; and C, fasting glucose after dapagliflozin (dashed line, white circle), exenatide (dotted line, black square), dapagliflozin and exenatide (dash-dotted line, upward white triangle), and placebo (black line, downward black triangle) after 10 days, 8 weeks, and 16 weeks of treatment. Data points represent mean with SEM. Statistically significant mean differences of treatments compared with placebo corrected for baseline values are indicated as * (P < 0.05), ** (P < 0.01), *** (P < 0.001).